Heart rate analysis in 24 patients treated with 150 mg amitriptyline per day

• Published in: Psychopharmacologia 1994-09, Vol.116 (1), p.110-114
• Main Authors: RECHLIN, T, CLAUS, D, WEIS, M
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aging - physiology; Amitriptyline - adverse effects; Amitriptyline - therapeutic use; Autonomic Nervous System Diseases - chemically induced; Autonomic Nervous System Diseases - physiopathology; Biological and medical sciences; Depressive Disorder - drug therapy; Depressive Disorder - physiopathology; Drug toxicity and drugs side effects treatment; Electrocardiography - drug effects; Female; Heart Rate - drug effects; Humans; Hyperventilation - physiopathology; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Psychiatric Status Rating Scales; Toxicity: cardiovascular system; Valsalva Maneuver - physiology
• ISSN: 0033-3158; 1432-2072
• DOI: 10.1007/BF02244880

Twenty-four patients treated with 150 mg amitriptyline per day for an episode of major depression underwent a standardized heart rate analysis (HRA) before therapy and after 14 days. The battery of cardiovascular reflex tests included the determination of the coefficient of variation (CV) while resting and during deep respiration, a spectral analysis of heart rate, the heart rate response to standing, and the Valsalva manoeuvre. The results of the initial HRA did not differ from a group of 24 normal control subjects matched for age and sex. On day 14 of treatment the patients showed significantly reduced values of heart rate variability in all tests (P < 0.0001), probably due to the anticholinergic side effects of amitriptyline. Heart rate increased from 78.1 to 93.6 bpm on average (P < 0.0001). Abnormal CV at rest was registered in 96% of the patients; during deep respiration 29% showed abnormal CV results. An abnormal spectral analysis was found in 100% of the cases (low frequency peak: 42%, mid-frequency peak: 100%, high frequency peak: 79%). The heart rate response to standing was abnormal in 75% and the Valsalva test in 33% of the cases. Eighty-eight percent of the patients fulfilled the criteria of a cardiovascular autonomic neuropathy under the conditions of amitriptyline therapy. As yet, the consequences of these changes for the patients have not been sufficiently elucidated.